TAK 792

Drug Profile

TAK 792

Alternative Names: TAK-792

Latest Information Update: 05 Apr 2017

Price : $50

At a glance

  • Originator Takeda
  • Class Obesity therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Obesity

Most Recent Events

  • 13 Mar 2017 Takeda, the Innovation Network Corporation of Japan and MEDIPAL HOLDINGS CORPORATION agree to establish joint venture company SCOHIA PHARMA for development of eight of Takeda's products including TAK 792
  • 01 May 2015 Takeda plans a phase I trial in Healthy volunteers in Japan (NCT02448719)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top